Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
KYKyntra Bio, Inc. logo

Kyntra Bio, Inc. (KYNB)

NASDAQ Global Market · Currency in USD
$4.58 ▼ -0.64 (-12.26%)
At close: Oct 23, 4:00 PM ET. Market closed.
$4.60 ▲ +0.02 (+0.43%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$5.22
Open
$5.09
Day's Range
$4.56 – $5.09
52 Week Range
$4.56 – $11.39
Volume
43,819
Avg. Volume
18,815
Market Cap
$18.55M
Beta (5Y Monthly)
1.05
PE Ratio (TTM)
0.08
EPS (TTM)
$45.25
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$28.00

Profile: Kyntra Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
34
CEO
Thane Wettig

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$3.55 · Revenue est. $1.77M
DateEst.Actual
Aug 13, 2026-$3.18$2.96Beat
May 11, 2026-$3.36-$3.74Miss
Mar 16, 2026-$3.89-$3.51Beat
Nov 10, 2025-$4.01-$1.61Beat
Aug 11, 2025-$2.25-$3.38Miss
May 12, 2025$0.75$0.05Miss

Analyst view

Consensus price target
$28.00 ▲ +511.3%
Range $28.00 – $28.00
Rating: Hold
Buy 33% · Hold 53% · Sell 13%

Get free alerts on KYNB and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.